Chicago, Illinois
CNS clinical trials in Chicago, IL
110 CNS studies are recruiting participants at sites in Chicago as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Chicago at a glance
- 110 studies are recruiting at a site in Chicago.
- By phase: Phase 1 (2), Phase 1/2 (2), Phase 2 (15), Phase 2/3 (1), Phase 3 (42), Phase 4 (4), No phase (30), Observational (14). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (68), university, hospital or other (42).
- By research area: Depression (43), Schizophrenia (19), Parkinson's Disease (16), Multiple Sclerosis (15), Epilepsy (7), Migraine (5), Bipolar Disorder (3), ADHD (2).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Chicago
Basic details from each study's public record (the 30 most recently updated of 110). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- Rush University
- Registry record
- NCT06793397 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study sites
- Rush University Medical Center · University of Chicago Medical Center
- Registry record
- NCT07002034 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Uptown Research Institute
- Registry record
- NCT07592689 · updated
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- LivaNova
- Study site
- Rush University Medical Center
- Registry record
- NCT03887715 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study sites
- Advocate Illinois Masonic Medical Center · Northwestern University · Rush MD Anderson Cancer Center
- Registry record
- NCT06748222 · updated
Our Voices Matter: Intervention for Depression in Youth
- No phase
- Ages 15 to 20
- All sexes
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Study site
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Registry record
- NCT07216326 · updated
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- Phase 3
- Ages 10 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Registry record
- NCT06372964 · updated
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Northwestern University
- Registry record
- NCT06559306 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Chicago Research Center
- Registry record
- NCT07573176 · updated
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Charter Research - Chicago
- Registry record
- NCT07775300 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Chicago, IL on ClinicalTrials.gov.
Schizophrenia studies recruiting in Chicago
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Phase 3
- Ages 13 to 17
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- EmVenio Research Center - Prime Healthcare
- Registry record
- NCT07288567 · updated
A Study to Evaluate the Effect of KarXT on Urological Safety
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study sites
- Pillar Clinical Research -Chicago · Uptown Research Institute
- Registry record
- NCT07221877 · updated
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
- No phase
- Ages 18 to 59
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- The University of Chicago
- Registry record
- NCT07853807 · updated
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- EmVenio Research Center - Prime Healthcare
- Registry record
- NCT07424404 · updated
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Phase 1
- Ages 18 to 60
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Uptown Research Institute
- Registry record
- NCT07615426 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Chicago, IL on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Chicago
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Pillar Clinical Research -Chicago
- Registry record
- NCT07140913 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Chicago, IL on ClinicalTrials.gov.
ADHD studies recruiting in Chicago
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Study site
- Ann & Robert H. Lurie Children's Hospital of Chicago
- Registry record
- NCT03047369 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Chicago, IL on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Chicago
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Boston Scientific Corporation
- Study site
- Rush University Medical Center
- Registry record
- NCT02071134 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Illinois Cancer Center ( Site 0044)
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Chicago Medical Center ( Site 5002)
- Registry record
- NCT06952504 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- The University of Chicago Medical Center ( Site 0118)
- Registry record
- NCT06623422 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Northwestern University Feinberg School Of Medicine
- Registry record
- NCT07174310 · updated
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- Phase 3
- Ages 45 to 75
- All sexes
- Sponsor
- BlueRock Therapeutics
- Study sites
- Parkinson's Disease and Movement Disorders Center at Northwestern Memorial Hospital · Rush University Medical Center - Neurology
- Registry record
- NCT06944522 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Northwestern Medical Group, Department of Neurology
- Registry record
- NCT06680830 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Chicago, IL on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Chicago
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Chicago, IL on ClinicalTrials.gov.
Epilepsy studies recruiting in Chicago
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Registry record
- NCT07594119 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study sites
- Rush University Medical Center · University of Chicago
- Registry record
- NCT05135091 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Chicago, IL on ClinicalTrials.gov.
Migraine studies recruiting in Chicago
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Cedar Crosse Research Center · Chicago Headache Center & Research Institute
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- Cedar Crosse Research Center · Chicago Headache Center & Research Institute
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Chicago, IL on ClinicalTrials.gov.
Ask about studies near Chicago
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections